More serious risks discussed in class labeling include pancreatitis and gallbladder issues, and the approved products carry contraindications related to a personal or family history of medullary thyroid carcinoma or MEN 2
Gastrointestinal side effects are the most common issues with GLP-1 receptor agonists, affecting up to 4050% of patients
Patients with type 2 diabetes benefit from dual indication coverage under insurance
However, you should always consult a healthcare professional to establish a weight loss regimen
Most symptoms are mild to moderate and improve significantly within 4-8 weeks of starting treatment or after dose adjustments
Injectable GLP-1 medications currently have a stronger and more established evidence base for weight loss, but oral options are showing meaningful results in clinical trials: In the head-to-head SURMOUNT-5 trial, researchers reported injectable tirzepatide had a mean weight reduction of about 20.2% at 72 weeks, compared with roughly 13.7% for injectable semaglutide